Progress in research and development of class 1.1 new drugs in China in the first half of 2014

In the first half of 2014, a total of 37 new drugs of category 1.1 were applied for clinical application, and Hengrui ranked first with three molecules of shr3680, shr4640 and shr6390 Most of the new drugs are me too, the most popular indication is tumor, and the most popular target is still tyrosine kinase In the first half of 2014, only two new drugs of category 1.1 were applied for production The p-toluenesulfonamide of HongRi pharmaceutical was used for intratumoral injection It is a question whether CFDA has the courage to approve the drug and whether doctors are willing to use it Benzcycloquinium bromide of Yingu pharmaceutical has a wide range of application population, but it may not have a therapeutic advantage compared with various couplets of foreign enterprises Ginkgo tree pharmaceutical and Geli biology have applied for NS3 / 4A protease inhibitors, and I don't like this kind of anti hepatitis C drugs On the one hand, NS3 / 4A protease inhibitors need to be combined with interferon, on the other hand, such self-developed anti hepatitis C drugs are on the market, and the patent of pure oral anti hepatitis C drugs developed by foreign companies has expired I am more interested in amoquini, f573, c-Met inhibitor, fg-4592, cvi-lm001, and ditinib They are aimed at the unsolved problems at home and abroad Of course, the risks are also great They test the R & D ability of enterprises Drug name, action target, indication, manufacturer category, hair generating peptide Clinical application of hs-10220 Na ulcer by Zhaoke pharmaceutical Jiangsu Haosen pharmaceutical declared clinical amoquini salt corticosteroid receptor antagonist chronic kidney disease Shandong Henri medicine Application for clinical application of long-acting GLP-1 analogue of Ibn for type II diabetes Application for clinical application of Ginkgo biloba Pharmaceutical Co., Ltd infected by HCV NS3 / 4A protease inhibitor Application for clinical imitavir by Guangdong dongyangguang Influenza virus NA inhibitor: Guangdong dongyangguang declares the clinical application of eugliptin DPP-4 inhibitor Clinical f573 caspase inhibitor liver failure declared by Chengdu Yuandong Pharmaceutical Co., Ltd of type II diabetes Shanghai Ruixing gene application clinical pyruvate sodium Na chronic obstructive pulmonary disease Jiangsu Changtai Pharmaceutical Co., Ltd Application for clinical application of bpi-9016 c-met inhibitor for lung cancer and gastric cancer Shr3680 androgen receptor inhibitor prostate cancer Jiangsu Hengrui medicine declared clinical dp-vpa Prodrugs of valproic acid for epilepsy Clinical application of mitoxantrone anthracycline anticancer drug for prostate cancer in Suzhou Shenyang Pharmaceutical University applied for clinical peg-sn38 top I inhibitor breast cancer and pediatric cancer Zhejiang Haizheng Pharmaceutical Co., Ltd Clinical application shr4640 Na gout Jiangsu Hengrui medicine clinical application Maihuatini tyrosine kinase inhibitor tumor Hangzhou Huadong medicine application clinical hydroxypiperone 5-HT1A receptor agonist / 5-HT reuptake inhibitor depression Zhejiang Huahai pharmaceutical declared clinical sklb1028 EGFR / FLT3 / ABL inhibitor Application of buretinib c-met inhibitor tumor by non-small cell lung cancer group Clinical application of ceftoren and cephalosporin antibiotics in Beijing puruno Application for clinical application of l-ornidazole ester, nitroimidazole antibiotics, bacterial infection, Shaanxi synthetic pharmaceutical industry application for clinical application Application and production of Yingu pharmaceutical for chronic obstructive pulmonary disease Clinical application for asc08 HCV by Haikou pharmaceutical factory Clinical application of fg-4592 hif-ph inhibitor for NS3 / 4A protease inhibitor HCV infection Clinical application of PI3K / HDAC double target immunosuppressant for blood cancer Application for clinical application of Guangzhou bebet Clinical application of tpn171h PDE5 inhibitor for erectile dysfunction and pulmonary hypertension Vecagel P2Y12 receptor inhibitor